Entyvio 108 MG/0.68 ML pen 0.68ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQT7C
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,547
Award facts
- Contract value 100% obligated
- $15,547.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $15,547.32 delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 6, 2026, for the supply of Entyvio 108 mg/0.68 mL pens with an ultimate completion date of January 28, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
Entyvio (vedolizumab) is a biologic immunosuppressant used in the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease. As a critical pharmaceutical supplier to the Department of Defense, AmerisourceBergen routinely fulfills delivery orders for specialty medications, brand-name drugs, and medical supplies across multiple therapeutic domains to support military treatment facilities and veterans' healthcare programs. This transaction reflects the company's ongoing role as a preferred vendor within the federal medical supply chain, leveraging its established IDC with DLA to efficiently deliver essential pharmaceutical commodities to government healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FQT7C?
SPE2DR26FQT7C was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FQT7C worth?
The government has obligated $15,547 on SPE2DR26FQT7C.
Is contract SPE2DR26FQT7C an order under another contract?
Yes. SPE2DR26FQT7C is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQT7C competed?
The extent of competition for SPE2DR26FQT7C was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award